INTRODUCTION
The concept of "cloning" comes originally from the Greek and in the medical sense means asexual generation, that means copying of the same individuals, reproduction of the same cells, same molecules and thus of the same living beings. The concept of cloning applies to uni-cellular organisms, plants, animals, and to human beings as well. Cloned siblings can only be either all females or all males, and are of the same sex as the donor. Monozygotes, that is, twins or multiple siblings arising from a single fertilized egg cell are considered human clones that nature itself is creating, although very rarely.
CLONING AND REPRODUCTION
From a biological and technical point of view, the cloning of mammals-unlike in plants-cannot be es- 1 Department of Gynaecology and Obstetrics, University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria; e-mail: johanna.ulmer@uibk.ac.at tablished exclusively from individual somatic cells in order to create directly from these cells a living being. In mammals, cloning requires the egg cell or oocyte and early blastomeres (embryonic cells). So far, only these cells are in a position to ensure the origin of mammalian life. The nuclear genome must be removed from the egg cell, thus being "enucleated" by microsurgical procedure. What remains is the cytoplasmic envelope of this egg cell into which the nucleus from an embryonic or adult cell is transferred by different methods. The cloning procedure can be repeated several times. In mammals, one of the limiting factors is the small number of oocytes available. Enucleated oocytes with donor genomes can be cultured in vitro for several days. The cloned embryos are then implanted in the uterus of surrogate females. The surrogate mothers give birth to offspring which are genetically identical with the original donor cells. Reproductive cloning in mammalian animals can be traced back to 1981 when such experiments were performed successfully in mice using embryonic cell nuclei from the inner cell mass of blastocysts for their tranplantation into enucleated egg cells (1) . At that time, this discovery sparked a worldwide dispute with arguments for and against cloning. In 1984, further experiments on cloning mice with embryonic cells as nuclear donors from preimplantation stages gave negative results. For this reason, the authors argued against the feasibility of cloning mammals via nuclear transplantation, concluded that "the cloning of mammals by simple nuclear transfer is biologically impossible" and finally hypothesized that "the inability of cell nuclei from these stages (preimplantation) to support development reflects rapid loss of totipotency" (2) . These negative findings influenced profoundly and stagnated temporarily further progress in the field of reproductive cloning. "Many people were deterred by this statement from pursuing mammalian cloning further" (3) . In 1986, however, cloned sheep that derived from embryonic cell nuclei transferred into enucleated oocytes demonstrated very impressively the applicability of cloning procedures for farm animals (4) . Consequently, in 1987, reproductive cloning procedures have been introduced to bovines (5); in 1989, to pigs (6) ; and in 1991, to goats (7) . Since then, steady progress in improving the cloning procedures has been achieved by the use of unfertilized and activated oocytes rather than fertilized egg cells, by the application of electrofusion for transfer of donor cell nuclei instead of their microsurgical injection into enucleated oocytes and by modification of culture medium and culture conditions for in vitro growth of cloned preimplantation embryos. In addition, further progress in microsurgical procedures on mammalian preimplantation embryos has opened up new avenues for a wide range of applications in reproductive medicine (Fig. 1) .
In 1993, cloning of human embryos was initiated via embryo splitting into individual blastomeres (8) . For their protection these early embryonic cells were surrounded by Na-alginate, a polysaccharide, as artificial zona pellucida. The individual blastomeres divided and developed further into morula-like structures during a few days in culture. These cloning experiments were carried out with nonviable, chromosomally abnormal (triploid) human embryos obtained rarely after in vitro fertilization in assisted reproduction programs. Reproductive cloning via embryo splitting following in vitro fertilization implies several novel and adventageous options. One embryo can be taken for uterine transfer whereas its cloned twin embryo can be cryopreserved for future stem cell production or another uterine transfer. The twin embryo may also be examined molecularly and cytogenetically for genetic and chromosomal anomalies or for its sex (Fig. 2) . Furthermore, a combination of reproductive cloning procedures may be envisaged by creating-through nuclear transfer from a donor cell into an enucleated oocyte-a cloned early embryo and then splitting it to obtain multiple cloned embryos. Future application of such technology to human reproduction remains extremely controversial from a scientific and ethical point of view.
Let us return to the history of mammalian cloning. In 1993, the birth of mice was reported following transplantation of early cell-cycle stage embryonic nuclei into enucleated oocytes (9) . In 1994, the first cloned calves originated from bovine inner cell mass cells as donor nuclei (10) . In 1996, sheep were cloned by nuclear transfer from cells of a cultured cell line (11) . In 1997, the same Scotish research group reported the birth of a mammal cloned for the first time from a somatic cell of an adult animal (12) . The cloned sheep "Dolly" originated genetically from an ewe's udder cell. In the meantime, Dolly has given birth to viable and healthy offspring. Also in 1997, cloned lambs were produced from an established embryonic cell line using its cells as nuclear donors between passages 8 and 16 of in vitro culture (13) . In the same year, rhesus monkeys were cloned from embryonic stem cells functioning as nuclear donors (14) . In 1998, it was reported in mice that embryonic cell nuclei from the inner cell mass and trophoblast were able to induce development in enucleated oocytes and promote differentiation up to the adult stage (15) . Again in 1998, the same Japanese research group reported that eight cloned calves were born and originated from somatic cells of a single cow (16) . Most impressively out of 10 embryos transferred to uteri of surrogate cows eight calves were born viable and normal. Three of them derived from oviductal cells and five of them from cumulus cells. In the same year, similar results were obtained in mice using successfully adult cumulus cells as nuclear donors for cloning adult murine offspring (17) . These results in sheep, bovines, and mice clearly demonstrated that nuclei from some adult cells retain their full genetic potential to bring about development of viable offspring.
In 1999, the first interspecies mammalian embryos were cloned (18) . Skin fibroblast cells from cattle, sheep, pig, monkey, and rat were used as sources of donor nuclei for their transplantation into enucleated bovine oocytes. Although some of the interspecies karyo-cytoplasmic hybrids developed into late preimplantation embryos and induced pregnancies in surrogate females, none of them advanced to fetal stages. Nevertheless, these first attempts to create interspecies clones document that early developmental mechanisms underlying and regulating early embryogenesis seem to be conserved among mammalian species. Future application of closely related mammalian interspecies cloning might be envisaged to substantially help saving or recreating endangered or almost extinct mammalian species.
At the beginning of 2000, results were published on the cloning of calves derived from nuclei of adult fibroblast cells cultured in vitro for 3 months (19) . These cells, when cultured over such a long period of time, still maintained their normal (diploid) set of chromosomes. This represented a significant progress for cloning procedures with established cell cultures. One caveat for the use of cultured cells in reproductive cloning is linked to the finite number of mitotic cell divisions leading to replicative senescence. It was proposed that among other factors the shortening of telomeres at the end of chromosomes is responsible for cellular aging and is causing chromosomal rearrangement (20) . Usually, the length of telomeric TTAGGG repeats is controlled and maintained by telomerase, a reverse transcriptase, by the telomeric protein TRF1 and tankyrase, a poly (ADP-ribose) polymerase (21, 22) . In recent experiments on human cell cultures, it was impressively demonstrated that after transfecting cells with human catalytic telomerase, chromosomal ends became extended by their telomeric repeats resulting in cells that continued to devide and exceeded their normal lifespan by at least 20 additional doublings (23) . As pointed out for future opportunities in therapeutic medicine, the ability to rejuvenate human cells with telomerase may provide new applications in the context of therapeutic cloning.
It is important to mention that the rate of success for viable adult mammalian clones using adult cells as nuclear donors is rather low and usually does not exceed 8%. Further insight into the complex biological and molecular interactions between donor cell and recipient egg cytoplasm following nuclear transfer into enucleated ooplasts or mitotic cytoplasts is required to improve reproductive cloning (24) . In this respect several criteria such as karyoplast-cytoplast volume ratio (25) , remodelling of transplanted donor nuclei under the influence of recipient cytoplasm and its effect on reprograming the donor genome (26, 27) , coordination of cell cycle and expression of its control proteins (28, 29) are of utmost importance for the outcome of cloning. Recently, modified culture conditions for donor cells as well as cloned embryos have shown to profoundly influence the cloning efficiency. It has been proposed that sheep donor cells arrested and synchronized in GO phase of the mitotic cell cycle via serum starvation may provide a more efficient source of cells for nuclear transfer due to a more readily facilitated reprograming of the nuclear genome in egg cytoplasm (30) . In comparative cloning studies using either starved or nonstarved bovine fibroblast cells, it was found that nuclei from starved donor cells supported significantly better the development of cloned embryos when compared with those from nonstarved cells, thus leading to higher pregnancy rates (31) . In addition, cloning efficiency could be increased by using the cloned bovine embryos for another recloning procedure. Along these lines it was shown in goat that several recloning events using early embryonic cell nuclei from already cloned embryos for another transfer into enucleated oocytes improved significantly the developmental potential of cloned embryos up to the adult stage (32) . By applying this cloning technique the authors reported the birth of 45 normal goats derived from 141 serially cloned embryos, a truly impressive result. Historically speaking, such serial nuclear transfers have been successfully pioneered in cloning experiments of Amphibia (33) .
The biological effects of mitochondrial contributions from recipient egg cytoplasm and nuclear donor cell on further development have so far rarely been investigated on cloned domestic animals. It has been suggested that mitochondrial heteroplasmy may be partially responsible for the elevated death rate in animal clones. Interestingly, quite variable and unpredictable proportions of mitochondrial heteroplasmy was recently reported for the recipient to donor mtDNA ratio in healthy cloned calves, ranging from about 0.4 to 4% with respect to donor mtDNA contributions, utilizing allele-specific nucleotide polymorphism to distinguish between both mtDNAs (34) . These results clearly demonstrate that mitochondrial heteroplasmy does not necessarily impede normal mammalian development. In other investigations, mitochondrial homoplasmy was revealed in several cloned sheep that contained exclusively mtDNA from the recipient egg cytoplast and none of the mtDNA from the nuclear donor cell (35) . The molecular events leading to such preferential mtDNA loss during cloning are still unknown. It was proposed that multiple passaging of donor cells during their in vitro culture may cause a continuous depletion of mtDNA. However, the process of loosing mtDNA of the donor cell type is not comparable to the process proposed to exclude sperm-derived mtDNA during fertilization (36) .
Several factors at risk have been associated with in vitro culture and reproductive cloning of embryos from domestic animals (37) . Immunohistochemical and cytogenetic studies on in vitro-cultured cattle and swine embryos showed a high incidence of developmental aberrations in comparison to in vivo development, thus signaling adverse effects of the in vitro procedures (38) . Culture conditions have shown to profoundly influence the developmental behavior of sheep and bovine embryos cultured in vitro for several days. After their uterine transfer some of them gave rise to fetal oversize (39, 40) . Similarly, some of the embryos from these farm animals when co-cultured with somatic cells for several days again developed into large-sized fetuses (41) . When sheep and bovine embryos were cultured in medium supplemented with human serum and then transferred in uteri, a significant incidence of fetal and placental anomalies, dystocia and neonatal death, limb deformation, and organ dysfunction was observed in the resulting large offspring (42) . Furthermore, postnatal growth leading to large offspring (LO syndrome) was reported to be greater in sheep originating from embryo culture including serum in comparison to naturally-bred controls (43) . Morphological investigations on some of the cultured embryos have revealed structural changes at the cellular level (44) as well as alterations in their kinetics of development (45) . It has been argued that embryonic abnormalities due to in vitro culture and developmental asynchrony between the transferred embryo and the uterine environment are causing elevated abortion rates. Consequently, culture conditions had been modified and improved to reduce or avoid some of these detrimental effects on fetal and postnatal development (46) . It should be emphasized that comparable pre-or postnatal development malformations and increased abortion rates have not been observed in human assisted reproduction, neither in IVF nor ICSI (47) . Analogously and in this context, another example of discrepancy is referring to progesterone treatment for sustaining uterine embryo implantation in reproduction. Whereas in sheep, administered progesterone during the first days of pregnancy triggered enhanced fetal growth (48) , such effects have not been observed during human fetal life despite the fact that progesterone is routinely administered to patients in assisted reproduction to improve uterine implantation after embryo transfer.
Concerning risk factors related to reproductive cloning of farm animals (Fig. 3) , it was reported from several groups that a significant proportion of cloned offspring showed abnormally elevated birth weights leading to the so-called large offspring (LO) syndrome (49, 50) . However, the incidence of this syndrome remains neither predictable nor reproducible. Among other biological parameters such as developmental asynchrony between the cloned embryo and the uterine environment, nonphysiological embryo culture conditions seem to be associated with and responsible for the LO syndrome. An increased rate of joint and limb abnormalities was seen on cloned animals with LO syndrome, most likely due to the oversize of fetuses that were cramped in uteri. Fetal overgrowth might also result from altered expression of imprinted genes (51) . However, the molecular mechanism underlying the LO syndrome in assisted animal reproduction is not analogous to human fetal overgrowth accompanied with the Beckwith-Wiedemann syndrome (52) .
Inappropriate culture conditions for some livestock embryos may cause epigenetic changes in genomic imprinting, thus leading to developmental anomalies. Similar for cloning procedures, inappropriate culture conditions for somatic donor cells and inefficient reprograming of nuclear donor genome in recipient egg cytoplasm may lead to long-lasting epigenetic changes in gene expression. Recently, it was demonstrated in sheep that LO fetuses showed a significantly reduced expression of IGF2R concomitantly associated with reduced methylation (53) . In particular, IGF2R expression in various tissues of LO fetuses was reduced by 30-60% in comparison to tissues from normal fetuses. Complete loss of methylation of the second intron (DMR2) region was found in most of the LO fetuses. Loss of DMR2 methylation in mice is causing a comparable reduction in IGF2R expression with a similar overgrowth phenotype, most likely induced by increased circulating levels of IGF2 (54) . Biomedical studies on some newborn domestic clones with phenotypic alterations led to the assumption that most likely organic abnormalities of energy metabolism in uteri had created abnormal fetal growth and poor physiological conditions for extrauterine life. It has been suggested that the metabolic dysfunctions observed in some of the cloned siblings may result from deleterious adaptations of the conceptus to abnormal placental functions and anomalies in placental size. As a consequence of this, elevated rates of late abortion, perinatal mortality and early postnatal death has been associated with the cloning of domestic animals. Organic defects such as heart and liver failures, cerebellar and lymphoid hypoplasia were diagnosed on some cloned livestock (55) . Until now it is still unclear and unsolved to what extent various embryo culture conditions, embryo cloning procedures, embryo transfer techniques, somatic donor cell treatment, and cell culture from adult tissue are causally related to artificial genomic imprinting and to particular developmental failures observed in domestic animal cloning. It is puzzling to observe in the farm animal system accumulated fetal and adult malformations including the LO syndrome after embryo culture in medium supplemented with serum and/or co-culture with feeder cells. Further research is needed to reveal plausible mechanisms for understanding and diagnosing these developmental anomalies observed in some livestock offspring. Recent improvements in human embryo culture using modified and serum-free media enhanced impressively the growth rate of human embryos up to the blastocyst stage (56) . In addition it was found that changing the medium during human embryo culture further improved the results in vitro, thereby adopting effectively the respective and sequential medium to the different physiological conditions required for embryonic growth (57) . This seems rather logical because during development in vivo, the embryo is getting exposed to different nutritional environments during its migration from the oviduct to the uterus. It should again be reinforced that during all the past years of worldwide human embryo culture for assisted reproduction, no elevated developmental abnormalities have been observed in the newborn IVF or ICSI offspring beyond and above the usual rate generally obtained among spontaneously born infants. It is therefore currently neither appropriate nor justified to extrapolate possible culture-induced fetal and adult malformations in farm animals to the human system. A possible extension of reproductive cloning to humans, however, seems highly controversial for biological and ethical reasons and is currently under worldwide debate.
CLONING AND THERAPY
Recently, it has become possible to successfully culture embryonic cells from 5 to 6 days old human preimplantation embryos and primordial germ cells from 5 to 9 weeks old human embryos in suitable nutritional media (58) . Embryonic stem (ES) cells and primordial germ (PG) cells remain diploid and conserve their embryonic and proliferative characteristics over many cell divisions in culture. ES cells are derived from the inner cell mass (ICM) of cultured human blastocysts produced by in vitro fertilization for clinical purposes in assisted reproduction and donated by patients. When blastocysts hatch from the zona pellucida and outgrow with their externally surrounding trophoblast cells, internal clusters of ICM cells can be isolated and cultured separately. Human ES cell lines can be established by selecting and expanding individual ICM colonies of uniform and undifferentiated morphology. Human embryo-derived ES cells may be employed for future therapeutic purposes to reconstitute defective organ systems since they are capable of differentiating into a variety of tissues and possess a large regenerative potential. Therapeutic cloning with the aid of assisted reproduction technologies for the extraction and expansion of human ES cells will open up novel and quite controversial applicabilities for transplantation medicine. Therapeutic cloning may be performed by utilizing donated preimplantation embryos from IVF and ICSI programs (Fig. 4) or by creating embryos via nuclear transfer from patients' somatic cells into enucleated oocytes (Fig. 5) . The latter concept would offer a unique opportunity to establish patient-specific stem cells for regenerative therapy.
Human ES and PG cell lines express alkaline phosphatase and several cell surface markers inducing stages-pecific antigens characteristic for embryonic and undifferentiated cells. In addition, human ES cells synthesize high level of telomerase that is required for adding telomeric repeats to chromosomal ends and maintaining the mitotic activity of cells. Somatic cells usually show low level of telomerase, contain shortened telomeres after prolonged culture in vitro and finally terminate their proliferative divisions. The high level of telomerase activity in ES cells contrary to cultured somatic cells supports their capacity for elevated replicative life-span.
Although the human ES cell lines were not established clonally from individual cells but rather from morphologically homogenous cell populations, nevertheless they all expressed consistently the various cellular markers unique to ES cells, thereby providing strong evidence for functionally homogenous cell populations. When ES cells started to pile up under crowded culture conditions, they spontaneously differentiated and synthesized α-fetoprotein and human chorionic gonadotropin. When human ES cells were transplanted to immune-suppressed SCID-mice, they developed teratomas that contained a variety of tissue derivations from all three germ layers. These teratomas included gut epithelium, cartilage, bone, smooth and striated muscle, neural and stratified squamous epithelium, and enclosed clusters of undifferentiated stem cells, so-called embryonal carcinoma (EC) cells. In mice, teratomas are composed of a comparable variety of differentiated tissues and may also include EC cells. When these EC cells were transplanted individually into recipient mouse blastocysts, they populated clonally the developing embryos and participated normally to fetal growth giving rise to healthy chimeric mice (59, 60) . When nuclei from these EC cells were transplanted into enucleated mouse egg cells and oocytes, some of them were capable of inducing and promoting embryogenesis up to the blastocyst stage and showed a remarkable potential for embryonic development. These EC-clone embryos, however, were not transferred in uteri for further development but rather investigated biochemically and cytologically for the proof of successful nuclear transfer (61) . Over the years, unfortunately, the usefulness of EC cells as pluripotent stem cells for the study of mammalian developmental processes turned out to be rather limited with respect to their differentiation in vivo and in vitro.
In the nonhuman primate system, EC cells from rhesus monkey blastocysts were successfully established prior to human ES cells and showed similar morphological, biochemical, and developmental features including a quite comparable variety of differentiated cell types (62) . In addition, neural tissue differentiation could be observed morphologically and confirmed biochemically through the presence of neurofilament proteins and glial fibrillary acidic protein (63) . It was proposed to utilize rhesus monkey ES cells lines as model system to investigate human differentiation and develop therapeutic cloning strategies for human diseases. In the mouse system, ES cell technology had been pioneered already 20 years ago and effectively applied to examine a variety of aspects of mammalian development (64) . However, due to a number of significant differences between mouse and human development, nonhuman primate ES cells reflect much more favorably our own cellular behavior and will provide a unique opportunity to test the safety and efficiency of therapeutic cloning for the treatment of specific diseases or organic lesions through in situ transplantation and application of clonally derived embryonic stem cells. Having safely developed the various strategies for therapeutic cloning in model systems (65) , there will be envisaged for the future a wide range of applications for human reproductive medicine that ultimately will help establish novel approaches for the treatment of patients via stem cell therapy (66, 67) .
CLONING AND DIAGNOSIS
With the introduction and first application of preimplantation genetic diagnosis (PGD) about a decade ago, reproductive medicine has reached new frontiers for medical diagnostic interventions (68, 69) . For couples with inherited defective genes or chromosomal anomalies and being enrolled in assisted reproduction programs, PGD has been developed to detect such heritable aberrations.
If there is genetic and medical indication for the performance of PGD, the severity of the disease in question, available therapy options, the prognosis of the hereditary disease as well as the presumed risk of the diseased gene being inherited by the offspring must be thoroughly investigated and clarified by genetic counselling. The application of PGD lies in the area of assisted reproduction and should be made available to couples with an elevated risk of having children with severe diseases of heritable origin. Another potential application of PGD might be envisaged for older women with significantly elevated and age-related risk for chromosomal aneuploidy during oocyte-meiosis. Undoubtedly, PGD has also its applicability in ethnic groups with an accumulated high frequency of specific types of gene mutations. In the Eurasian population cystic fibrosis (CF) and spinal muscular atrophy (SMA) with a 1 in 50 ratio for heterozygotic carriers are the most frequent autosomal recessive gene defects, in the Mediterranean region thalassemia and hemophilia show an elevated frequency, in the Jewish population the heritable Tay-Sachs disease is preferentially elevated, and in the African-American population sickle cell anemia with an elevated frequency of about 8% carrier status is a severe progressive disease and one of the most common genetic disorders.
PGD offers the early examination of genetic defects on biopsied polar bodies of the egg cells and biopsied blastomeres of the developing preimplantation embryos (70) . In addition, biopsied trophoblast cells from blastocysts can be submitted to PGD (71) . The great advantage of PGD resides in the early embryonic detection of parentally transmitted genetic and chromosomal anomalies before embryo transfer in utero. Only maternally contributed defects can be examined on the polar bodies of oocytes and fertilized eggs, whereas paternally and maternally derived defects can be both detected on blastomeres or trophoblast cells of preimplantation embryos (Fig. 6) . Without PGD, these defects can certainly be detected on cells of biopsied chorionic villus sampling during the 11th week of pregnancy or on harvested cells from amniocentesis about 4 weeks later. The presence of genetic and chromosomal anomalies represents a medical implication for legal abortion. With PGD, however, this physiological and psychological trauma of an induced abortion for couples with inborn errors at risk for heritable transmission and enrolled in assisted reproduction programs can almost entirely be prevented, since only the healthy and not the genetically defective embryo will be transferred in utero following IVF or ICSI treatment.
Sexing of embryos via PGD might be useful for those ICSI-enrolled couples with an infertile male partner carrying Y chromosome deletions that are responsible for his infertility. This defective Y chromosome will be transmitted to the ICSI sons becoming again infertile but not to the daughters. PGD should also be performed in those cases where Klinefelter (XXY) patients are enrolled in the assisted reproduction program to avoid the transmission of sex chromosomal aneuploidy to the offspring (72) . PGD performed on polar bodies for cytogenetic screening of common aneuploidies has led to the birth of healthy children (73) . With highly sophisticated micromolecular cloning techniques such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) methods, the biopsied cells can be analyzed within a few hours in order to determine the presence or absence of the hereditary gene defects or chromosomal alterations. Using molecular probes for X and Y chromosomes it is possible to reveal the sex of the embryos. In case of hereditary diseases where the defective genes are located on the maternal chromosomes, it is important to sex embryos since male (XY) embryos may carry the genetic defects on the maternally inherited X chromosome in a hemizygous fashion, leading to the phenotypic expression of the genetic defect. Female (XX) embryos, on the other hand, can be considered as balanced carriers since they may contain the defective maternal X chromosome together with the inherited normal paternal X chromosome.
Concerning structural chromosomal anomalies, balanced reciprocal translocations are quite frequently observed in one of every 500 live births.
Phenotypically, normal carriers of such translocations may have an elevated risk of transmitting unbalanced chromosomal segments to the offspring. New screening techniques have been developed for PGD to visualize the translocated region on metaphase chromosomes using breakpoint-specific probes or sub-telomeric probes for the segments involved in a given translocation (74) . The more new probes Fig. 7 . A number of chromosomal aberrations and genetic defects can be analyzed using cytogenetic and molecular micromethods for detecting preimplantation anomalies via PGD.
will become available for detecting specifically chromosomal anomalies, the more chromosomal rearrangements including inversions and deletions will be amenable to cytogenetic analysis in PGD. The same holds true for molecular probes that specifically recognize genetic alterations. Currently, quite a number of heritable diseases and inborn metabolic dysfunctions caused by a single gene defect can be examined via PGD and this diagnostic repertoire will certainly be increased over the next years (Fig. 7) . PGD is becoming a powerful technique in assisted reproduction and provides a unique opportunity for carrier couples with the desire for a healthy child to avoid the painful decision of whether to abort a genetically or chromosomally affected fetus.
Future application of PGD can be projected to farm animal cloning to diagnose cells from cloned embryos for molecular defects of epigenetic changes that lead to developmental malformations. In this regard, early diagnosis of aberrant methylation of imprinted genes in cloned embryos from livestock can be taken as unequivocal criteria for their uselessness to transfer them in uteri. This diagnostic strategy should allow to significantly reduce the percentage of pre-and postnatal malformations and help to improve the developmental quality of cloned livestock offspring.
CLONING AND PHARMACEUTICALS
Rapid progress in basic research on mammalian gene technology such as excision of genes of genomic DNA with the help of specific restriction enzymes and molecular cloning with suitable retroviral vectors, incorporation of specific expression sequences, and functional integration of cloned genes in cultured mammalian cells have not only revolutionized the pharmaceutical industry but also animal husbandry.
Some of these new molecular technologies in genetic engineering have been successfully combined with farm animal cloning in order to create transgenic animals carrying an integrated foreign gene in its genome that can heritably be transmitted in a Mendelian fashion to subsequent generations of progeny. Over the past years, several strategies have been developed to produce transgenic livestock (75) . Historically viewed, the first successful attempts to transfect sheep and pigs with clonally derived foreign genes were achieved by microinjection of the for- eign DNA sequences into pronuclei of fertilized eggs (76, 77) . This technique enables to selectively inject the DNA into either the male or female pronucleus for chromosomal integration in either the paternal or maternal genome (Fig. 8) . The drawbacks of this strategy of transgenetics, however, have turned out to give a low rate of stable genomic integration, a random process of chromosomal insertion, undesirable insertional mutagenesis and variable expression of the foreign transgenes depending on their site if integration. Using the approach of DNA microinjection into the perivitelline space of metaphase II oocytes, following their fertilization, the births of transgenic cattle and rhesus monkeys have been reported recently (78, 79) .
Another route of transfection has been chosen to introduce foreign DNA into sperm which after fertilization will be integrated into the developing embryo and maintained in transgenic animals. However, the percentage of stable DNA integration into sperm is rather low and unpredictable, and random-insertion seems to be the rule (80) . Nevertheless, transgenic pigs carrying the human decay accelerating factor have recently been produced via sperm-mediated gene transfection (81) .
A more promising but rather complex approach to cloning of transgenic farm animals is referring to the transfection of cultured somatic cells with foreign genes and their clonal selection and expansion in vitro. The transfected cells can be analyzed for the presence and integration site of the particular transgene within their genome. Such cells can then be used for nuclear transfer into enucleated oocytes to produce clonally derived transgenic animals. Depending on the sex-chromosomal composition of the Fig. 9 . A variety of cloned human genes have been integrated into transgenic farm animals for pharmaceutical harvest and medical application of the synthesized human gene products. cultured nuclear donor cells, the cloned transgenic offspring will be entirely either females or males. This of course means, as an example, that cultured XX cells will be required for their genomic transfection if the biopharmaceutical protein is supposed to be harvested from the milk of cloned cows (82) . This strategy has already been applied successfully to create cloned transgenic sheep, goat, and cattle in utilizing genetically transfected cells for cloning (83) . Several recombinant human proteins are efficiently produced in cloned livestock and can be taken as biologically functional components for a wide range of human pharmaceutical applicabilities (Fig. 9) .
PERSPECTIVES
Recent progress in pharmaceutical cloning of transgenic farm animals has led to tremendous commercial opportunities. Quite a number of human gene products are already being synthesized in cloned livestock for pharmaceutical and therapeutic purposes and are already tested in various phases of clinical trials. This biomedical repertoire will certainly increase over the next years as the demands on human pharmaceutical proteins, vaccines, drugs, and hormones will steadily be growing worldwide. Genetically engineered organs and tissues from transgenic farm animals designed for xenotransplantations may be envisaged for future therapeutic applications in human medicine.
As far as future applications of nonhuman primate cloning are concerned, cloned monkeys with targeted gene defects will become useful and invaluable models for studying human diseases and developing new strategies for therapy. Future progress in cloning transgenic monkeys from genetically engineered ES cells in culture will significantly help to increase our knowledge in biomedicine. With respect to human therapeutic cloning in reproductive medicine, a novel discipline of biomedical treatments dedicated to stem cell therapy for a variety of human diseases will emerge for the benefit of patients' health. Our society will have to set up the medical, legal, and ethical rules concerning human cloning (84) . It is fairly predictable that the future will bring a wealth of exciting new applicabilities in the area of medical, therapeutic, and pharmaceutical biotechnology which in the first instance should prove to be advantageous for patients and which at the same time will result in further progress of reproductive medicine.
